What did @daviddemesquita actually say?
The creator walked through IGF-1 as a standalone compound for bodybuilding, splitting the conversation between two forms: IGF-1 DES and IGF-1 LR3. His core argument is that people take IGF-1 to pursue "muscle hyperplasia, which is the creation of new muscle tissue and cells," and that LR3 is the more practical option because of its longer half-life. He suggested a dosing range of 20 to 50 micrograms injected intramuscularly into the trained muscle group, and he flagged a concern he says is underreported: prolonged IGF-1 use may promote cancer cell growth. He was candid that "taking this is like gambling every day" and that a pump from IGF-1 does not confirm tissue growth is happening.
Credit where it is due: this is not a pure hype video. He flagged real risks, acknowledged uncertainty, and stopped short of promising results. That matters in a space full of guarantee-style content.
Does the science back this up?
Partially, but with some important nuance the video glosses over. The claim that IGF-1 drives muscle hyperplasia in adults is more complicated than presented, and the half-life figures he cites for DES versus LR3 are roughly consistent with the literature, though the picture is not as clean as he makes it sound.
IGF-1 does play a documented role in muscle cell signaling. Research from Barton-Davis et al. (1998, PNAS) showed IGF-1 overexpression in aged mice led to significant muscle mass recovery, but translating that to acute intramuscular injection in healthy adults is a large leap. The specific claim that hyperplasia, meaning actual new muscle cell creation, is a reliable outcome of exogenous IGF-1 in adult humans is not well-supported in controlled trials. Most evidence points to hypertrophy, enlargement of existing cells, rather than hyperplasia as the dominant mechanism. Fryburg et al. (1995, American Journal of Physiology) found IGF-1 infusion increased protein synthesis acutely, but hyperplasia as a confirmed end-point in humans remains largely theoretical.
On the cancer concern, he is on firmer ground. The IGF-1 signaling axis and cancer promotion is one of the more robustly studied areas in oncology. Pollak et al. (2004, Nature Reviews Cancer) detailed how IGF-1 receptor activation promotes cell survival and inhibits apoptosis in multiple tumor types. His instinct to flag this risk is correct.
What did they get wrong (or right)?
The half-life framing for DES versus LR3 is directionally right but oversimplified. IGF-1 DES has a shorter half-life, estimated at under 30 minutes in some models, while LR3 extends activity by reducing binding protein affinity, giving it a functional half-life closer to 20 to 30 hours. Those numbers support his practical point about DES being difficult to use around training windows. However, "longer half-life" in LR3 does not simply mean better or safer. It means systemic exposure is extended across all tissues, not just muscle, which is exactly the concern with cancer risk he raises later but does not fully connect back to LR3 specifically.
He also defines hyperplasia as "the creation of new muscle tissue and cells," which is a reasonable lay definition, but he presents it as a likely outcome rather than a speculative one. That framing overstates what the evidence shows for exogenous IGF-1 in adult humans. His own caveat, that a pump "doesn't necessarily mean tissue growth," is the more honest version of the claim and should have been the lead.
He deserves credit for naming the cancer risk unprompted and for not telling viewers this is definitively effective. That level of epistemic honesty is rare in bodybuilding content.
What should you actually know?
IGF-1 peptides, whether LR3 or DES, are not approved by the FDA for bodybuilding or body composition use. They are research compounds. That means no standardized manufacturing oversight, no guaranteed purity, and no clinical dosing data from controlled trials in healthy adults pursuing muscle gain.
The cancer risk the creator mentions is not a fringe concern. Elevated circulating IGF-1 has been associated with increased risk of colorectal, prostate, and breast cancers in epidemiological studies. Hankinson et al. (1998, Lancet) found a strong association between plasma IGF-1 levels and premenopausal breast cancer risk. If you already have undetected malignant cells, which by definition you would not know about, providing a growth-promoting signal is a serious gamble.
The intramuscular injection protocol he describes, targeting the trained muscle group, is based on anecdote and community observation, not peer-reviewed data. Localized hyperplasia from site-specific injection is a popular theory in bodybuilding circles but has not been confirmed in human trials. If you are considering any peptide therapy, that conversation belongs with a licensed medical provider who can review your full health history, not a TikTok comment thread.